Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Immersive Virtual Reality and Exercise Programs in Multiple Sclerosis: ExeRVIEM III (ExeRVIEM III)

28. juli 2026 opdateret af: Pablo Campo-Prieto, University of Vigo

Effects of a Physiotherapy Program With High-Intensity Exercise and Immersive Virtual Reality in Multiple Sclerosis: Randomized Controlled Trial

TITLE: Immersive Virtual Reality and Exercise Programs in Multiple Sclerosis: ExeRVIEM III. INTRODUCTION: Multiple sclerosis (MS) is a chronic neuroimmunological and degenerative disease characterized by demyelination within the central nervous system. Its clinical course involves motor impairment, sensory disturbances, cognitive dysfunction, and a progressive decline in functional independence. MS is one of the leading causes of non-traumatic disability in young adults. This highlights the considerable impact of the disease, both in terms of healthcare burden and healthcare expenditure. Within this context, therapeutic exercise has evolved from being considered potentially harmful to being recognized as a safe and effective intervention capable of improving gait, balance, cardiorespiratory fitness, fatigue, and quality of life in people with MS. A model has been proposed for prescribing and progressing exercise at different stages of MS: passive range-of-motion exercises designed for patients with the most severe symptoms, a second stage incorporating active muscle-strengthening exercises, and finally, integrated exercise programs that incorporate strength, endurance, balance, and coordination training. Evidence from systematic reviews and meta-analyses shows that structured exercise (including high-intensity protocols when performed under supervision) is safe and can improve functional outcomes. Our ExeRVIEM III project (Physiotherapy program with High-Intensity Exercise Program and Immersive Virtual Reality in Multiple Sclerosis) represents a novel strategy to facilitate rehabilitation exercise programs using head-mounted virtual reality displays. HYPOTHESIS: The ExeRVIEM III project, based on training physical function in people with MS, is feasible and safe, and could have a potential clinical impact in the motor and cognitive domains, as well as applicability in community settings, such as patient associations. GENERAL OBJECTIVES: 1.1 To design and implement an ExeRVIEM III exercise program/protocol for people with MS. 1.2 To evaluate the safety of the high-intensity virtual reality exercise program. SPECIFIC OBJECTIVES: 2.1 To analyze the possible changes in disability, functional variables, cognitive domains and biomarkers in the short and medium term in people who attend a patient association and carry out the ExeRVIEM III exercise program for people with MS. METHODOLOGY: A randomized controlled trial, double-arm (experimental and control group) study will be conducted at a patient association (Santiago de Compostela, Spain). The intervention will consist of an 6-month supervised virtual rehabilitation program, with two weekly sessions on alternate days, in addition to the standard rehabilitation prescribed by the patient association clinical team (physiotherapy, occupational therapy, and cognitive training sessions). An inmersive virtual reality (IVR) body combat exercise videogame will be used, administered via a virtual reality headset. In accordance with clinical guidelines for IVR, sessions will be intentionally brief (10 minutes) to minimize cybersickness and excessive fatigue. Assessments will be conducted at baseline (week 0) and immediately after the intervention (week 24). Demographic and clinical data will also be collected, including sex, age, comorbidities, disease duration, MS subtype, and pharmacological treatment. Assessments will be conducted at the patient association and in the Neurology Department of the referral hospital. Feasibility, safety, strength parameters, dual-task performance and fatigue levels assessments will be performed at the patient association by physiotherapists, while the remaining assessments will be completed at the hospital by a neurologist specializing in MS. The content of the assessments will be: Patient characteristics that will include data on age, sex, years since diagnosis, MS subtype, and pharmacological treatment. Feasibility: Number of virtual sessions attended by each participant (adherence rate via registration sheet). Rate Perceived Effort using the modified Borg scale, which measures the level of perceived exertion on a scale of 0 to 10 from no effort to maximum effort. Safety: adverse events using the Simulator Sickness Questionnaire (SSQ).Strength parameters using Five times sit to stand test (FTSST) and handgrip test. Functional mobility will be assessed using Timed and Go test (TUG) and with dual task performance using TUG-cog. Level of fatigue using the Fatigue Severity Scale (FSS). Level of disability: using the Expanded Disability Status Scale (EDSS).Gait will be evaluated using the 25Foot Walk Test (25FWT). Manual dexterity will be assessed using 9-Hole Peg Test (9HPT). Cognitive domains evaluated by the Symbol Digit Modalities Test (SDMT)Axonal injury biomarker evaluated by Neurofilament light chain (sNfL) concentrations.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

30

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Pablo Campo-Prieto, PhD
  • Telefonnummer: 986801770
  • E-mail: pcampo@uvigo.gal

Studiesteder

      • Pontevedra, Spanien
        • Rekruttering
        • University of Vigo
        • Kontakt:
          • Dr. Pablo Campo Prieto, PhD
          • Telefonnummer: +034 986801750
          • E-mail: pcampo@uvigo.gal

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • ≥18 years of age.
  • Confirmed diagnosis of MS.
  • Stable disease with no relapse in the previous 6 weeks.
  • Patients who will be take follow up by a neurologist at the referral hospital and will be members of the patient association.
  • Ability to perform moderate exercise.
  • Capacity to provide informed consent.

Exclusion Criteria:

  • Comorbidities that hinder the development of the VR program
  • Visual or vestibular impairment that would contraindicate VR use.
  • Recent changes in disease modifying therapy.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: ExeRVIEM III Protocol + Standard rehabilitation
Virtual exercise based program + Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognition sessions)
The intervention will consist of a supervised virtual rehabilitation program delivered over 6 months, with two sessions per week on alternating days. An Immersive Virtual Reality body combat-based exergame executed through a VR headset will be used.
Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognitive training sessions).
Aktiv komparator: Standard rehabilitation
Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognition sessions)
Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognitive training sessions).

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Level of disability using the Expanded Disability Status Scale (EDSS)
Tidsramme: Baseline
EDSS quantifies Multiple sclerosis (MS) related disability on a scale from 0 (normal neurological exa-mination) to 10 (MS related death). Lower scores indicate less disability and generally, and a change of between 0.5 and 1.0 points on the EDSS scale is considered clinically significant, indicating actual progression or improvement in disability.
Baseline
Level of disability using the Expanded Disability Status Scale (EDSS)
Tidsramme: week 24
EDSS quantifies Multiple sclerosis (MS) related disability on a scale from 0 (normal neurological exa-mination) to 10 (MS related death). Lower scores indicate less disability and generally, and a change of between 0.5 and 1.0 points on the EDSS scale is considered clinically significant, indicating actual progression or improvement in disability
week 24
Gait evaluated by 25Foot Walk Test (25FWT)
Tidsramme: Baseline
25FWT assesses walking speed over 25 feet; shorter times reflect better gait capacity. The 25FWT is a validated, reliable measure accepted by regulatory consortia, predictive of disability progression, where a change greater than 20% in the time taken to walk 25 feet (7.6 meters) is considered relevant to the patient's daily life, indicating a real improvement or deterioration of their functional capacity, beyond the natural variability of the test.
Baseline
Gait evaluated by 25Foot Walk Test (25FWT)
Tidsramme: Week 24
25FWT assesses walking speed over 25 feet; shorter times reflect better gait capacity. The 25FWT is a validated, reliable measure accepted by regulatory consortia, predictive of disability progression, where a change greater than 20% in the time taken to walk 25 feet (7.6 meters) is considered relevant to the patient's daily life, indicating a real improvement or deterioration of their functional capacity, beyond the natural variability of the test.
Week 24
Manual dexterity assessed by 9-Hole Peg Test (9HPT)
Tidsramme: Baseline
9HPT (right and left) evaluates fine manual dexterity. Lower times indicate better performance. Reductions of approximately 20% are often considered clinically meaningful, particularly in progressive Multiple sclerosis (MS) phenotypes. Often in clinical studies, a change of 2 seconds or more in the average test execution time is considered clinically relevant, indicating an impairment in manual dexterity and fine motor function
Baseline
Manual dexterity assessed by 9-Hole Peg Test (9HPT)
Tidsramme: Week 24
9HPT (right and left) evaluates fine manual dexterity. Lower times indicate better performance. Reductions of approximately 20% are often considered clinically meaningful, particularly in progressive Multiple sclerosis (MS) phenotypes. Often in clinical studies, a change of 2 seconds or more in the average test execution time is considered clinically relevant, indicating an impairment in manual dexterity and fine motor function
Week 24
Cognitive domains evaluated by the Symbol Digit Modalities Test (SDMT)
Tidsramme: Baseline
SDMT assesses cognitive processing speed; higher scores indicate better performance. The SDMT is highly sensitive to cognitive impairment in Multiple sclerosis (MS) and a variation of 4 to 5 points (or a change of at least 10% from baseline) is generally considered to indicate a real and clinically relevant change in the patient's cognitive performance
Baseline
Cognitive domains evaluated by the Symbol Digit Modalities Test (SDMT)
Tidsramme: Week 24
SDMT assesses cognitive processing speed; higher scores indicate better performance. The SDMT is highly sensitive to cognitive impairment in Multiple sclerosis (MS) and a variation of 4 to 5 points (or a change of at least 10% from baseline) is generally considered to indicate a real and clinically relevant change in the patient's cognitive performance
Week 24
Axonal injury biomarker evaluated by Neurofilament light chain (sNfL) concentrations
Tidsramme: Baseline
sNfL expressed in serum (pg/mL) evaluates disease progression. Lower levels suggest reduced neuroaxonal damage and may reflect decreased disease activity. In this study, it was performed using an automated assay for measuring sNfL.
Baseline
Axonal injury biomarker evaluated by Neurofilament light chain (sNfL) concentrations
Tidsramme: Week 24
sNfL expressed in serum (pg/mL) evaluates disease progression. Lower levels suggest reduced neuroaxonal damage and may reflect decreased disease activity. In this study, it was performed using an automated assay for measuring sNfL.
Week 24
Lower limbs strength evaluated by five times sit to stand test (FTSST)
Tidsramme: Baseline
FTSST is used to objectively determine measures to provide a method to quantify functional lower extremity strength and/or identify movement strategies a patient uses to complete transitional movement (5 repetitions standing up and sitting in a chair). Lower times indicate better performance.
Baseline
Lower limbs strength evaluated by five times sit to stand test (FTSST)
Tidsramme: Week 24
FTSST is used to objectively determine measures to provide a method to quantify functional lower extremity strength and/or identify movement strategies a patient uses to complete transitional movements (5 repetitions standing up and sitting in a chair). Lower times indicate better performance
Week 24
Functional mobility evaluated by five timed and go test (TUG)
Tidsramme: Baseline
TUG is a standardized test to assess the basic functional mobility of elderly persons and requires both static and dynamic balance. The patient is observed and timed while he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again. Lower times indicate better performance.
Baseline
Functional mobility evaluated by five timed and go test (TUG)
Tidsramme: Week 24
TUG is a standardized test to assess the basic functional mobility of elderly persons and requires both static and dynamic balance. The patient is observed and timed while he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again. Lower times indicate better performance.
Week 24
Dual task performance evaluated by five timed and go test- cognitive (TUG-cog)
Tidsramme: Baseline
It involves performing the TUG physical test while simultaneously carrying out a mental task (such as counting backwards in increments of three). It is an ideal tool for assessing the ability to multitask in older adults or individuals with neurological impairment. Lower times indicate better performance.
Baseline
Dual task performance evaluated by five timed and go test- cognitive (TUG-cog)
Tidsramme: Week 24
It involves performing the TUG physical test while simultaneously carrying out a mental task (such as counting backwards in increments of three). It is an ideal tool for assessing the ability to multitask in older adults or individuals with neurological impairment. Lower times better performance.
Week 24
Upper limbs strength evaluated by handgrip test
Tidsramme: Baseline
A handgrip strength test measures the maximum force your hand and forearm muscles can make. It acts as a key indicator for overall body strength and healthy aging. Higher scores indicates better performance.
Baseline
Upper limbs strength evaluated by handgrip test
Tidsramme: Week 24
A handgrip strength test measures the maximum force your hand and forearm muscles can make. It acts as a key indicator for overall body strength and healthy aging. Higher scores indicates better performance.
Week 24
Levels of fatigue evaluated with The Fatigue Severity Scale (FSS)
Tidsramme: Baseline
The FSS is a questionnaire with 9 questions that measures the extreme fatigue that affects many people with multiple sclerosis. Lower scores in the scale indicate less fatigue.
Baseline
Levels of fatigue evaluated with The Fatigue Severity Scale (FSS)
Tidsramme: Week 24
The FSS is a questionnaire with 9 questions that measures the extreme fatigue that affects many people with multiple sclerosis. Lower scores in the scale indicate less fatigue.
Week 24

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Pablo Campo-Prieto, PhD, University of Vigo

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

6. oktober 2025

Primær færdiggørelse (Anslået)

31. juli 2026

Studieafslutning (Anslået)

7. august 2026

Datoer for studieregistrering

Først indsendt

22. juli 2026

Først indsendt, der opfyldte QC-kriterier

28. juli 2026

Først opslået (Faktiske)

31. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

31. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner